Telix Targets $1.5 Bln Revenue In 2027 As ITM Deal May Accelerate Therapy Launch To 2027

Telix Pharmaceuticals Ltd. (TLX) is targeting approximately $1.5 billion in revenue in 2027, including the anticipated contribution from its proposed ITM acquisition. In late September, Telix announced an upcoming merger with ITM Isotope Technologies Munich SE, a supplier of therapeutic radioisotopes, in a deal worth up to $2.35 billion. At an investor event in Melbourne, a managing director of the radiopharmaceutical company stated that ITM could strengthen its isotope supply capabilities and bring its planned first commercial therapeutic launch forward to 2027 from 2028. Telix expects approximately $50 million in synergies within two years of combining the businesses, as ITM's lutetium-177 manufacturing operations are reportedly supported by supply contracts extending into the 2030s. The company also outlined progress across its cancer pipeline. The 120-patient OPTIMAL-PSMA study of TLX597-Tx in advanced prostate cancer has completed enrollment, with results expected in early 2027. Its Phase 3 ProstACT Global trial of TLX591-Tx is enrolling patients across multiple countries. In brain cancer, Telix is advancing TLX101-Tx in the Phase 3 IPAX BrIGHT trial for recurrent glioblastoma...